📈 Markets & Finance
Live
Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems
Written by Reuben Gregg Brewer for The Motley Fool -> Pfizer is a highly respected pharmaceutical company. The drug maker is dealing with a mismatch between its new drug development and patent expi…
Nasdaq News — 6 June 2026
Text:
24
0
0
The drug maker is dealing with a mismatch between its new drug development and patent expirations. Management is standing behind the dividend, and it
Read Full Story at Nasdaq News → Sources
📈 Markets & Finance
Sam Altman says OpenAI's top token spender uses 100 billion tokens a month — and they're not even the world leader
📈 Markets & Finance
Intel, AMD, Micron shares sink as Broadcom results spark semiconductor sector sell-off
📈 Markets & Finance
This Smart‑Money Legend Won Big on Intel. The Rest of His Portfolio Might Be Even More Revealing
📈 Markets & Finance
A new NJ bill would hand pet owners up to $900 in tax credits — and your state could be next
📈 Markets & Finance
Addressing Investor Transparency, Updates from Euronet Worldwide’s (EEFT) First Analyst Day in a Decade
📈 Markets & Finance
MGM Resorts stock jumps as Barry Diller's People Inc. makes bid to take over the company
